PMID: 39856Jan 1, 1979

Euhypnos Forte (temazepam) in insomniac patients: a clinical trial in general practice

The Journal of International Medical Research
H S Sussman

Abstract

In an open evaluation, soft gelatin capsules containing 20 mg temazepam (Euhypnos Forte) were administrated in doses of 40--60 mg to 134 patients from twenty-two general practices. The patients selected by the general practitioners werethose known to require hypnotics but in whom conventional doses had proven unsatisfactory. Of the 134 patients who entered the trial, 104 preferred the higher doses of two or three capsules. Eighty-eight per cent of these patients found Euhypnos Forte to be 'very good' or 'good' and 69% expressed preference for Euhypnos over their customary medication. Eighty-eight per cent of these patients experinces no hangover effect.

References

Jul 1, 1981·Pharmacotherapy·M M Mitler

Citations

Dec 16, 1977·European Journal of Clinical Pharmacology·L M FuccellaG Tognoni
Jan 1, 1977·The Journal of International Medical Research·L K Fowler
Jan 1, 1977·The Journal of International Medical Research·L K Fowler
Jan 1, 1976·The Journal of International Medical Research·A PinesJ F Rooney

Related Concepts

Anti-Anxiety Effect
Microcapsules Drug Delivery System
Family Medicine (Field)
Hypnotics
Temazep von ct
General Practice (Field)
Clinical Trials
Dropouts
Temazepam
Transient Insomnia

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.